Dulaglutide as an Effective Replacement for Prandial Insulin in Kidney Transplant Recipients with Type 2 Diabetes Mellitus: A Retrospective Review

Dulaglutide, a weekly injectable glucagon-like peptide-1 receptor agonist, has demonstrated effectiveness when combined with basal insulin. We examined whether the efficacy of dulaglutide is comparable to that of prandial insulin in kidney transplant (KT) recipients with type 2 diabetes mellitus (T2...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Hwi Seung Kim, Jiwoo Lee, Chang Hee Jung, Joong-Yeol Park, Woo Je Lee
Formato:	article
Lenguaje:	EN
Publicado:	Korean Diabetes Association 2021
Materias:	diabetes mellitus, type 2 dulaglutide insulin Diseases of the endocrine glands. Clinical endocrinology RC648-665
Acceso en línea:	https://doaj.org/article/e0a3db234543460e922178aa4c46167d
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e0a3db234543460e922178aa4c46167d
record_format	dspace
spelling	oai:doaj.org-article:e0a3db234543460e922178aa4c46167d2021-12-01T05:07:51ZDulaglutide as an Effective Replacement for Prandial Insulin in Kidney Transplant Recipients with Type 2 Diabetes Mellitus: A Retrospective Review2233-60792233-608710.4093/dmj.2020.0180https://doaj.org/article/e0a3db234543460e922178aa4c46167d2021-11-01T00:00:00Zhttp://www.e-dmj.org/upload/pdf/dmj-2020-0180.pdfhttps://doaj.org/toc/2233-6079https://doaj.org/toc/2233-6087Dulaglutide, a weekly injectable glucagon-like peptide-1 receptor agonist, has demonstrated effectiveness when combined with basal insulin. We examined whether the efficacy of dulaglutide is comparable to that of prandial insulin in kidney transplant (KT) recipients with type 2 diabetes mellitus (T2DM) undergoing multiple daily insulin injection (MDI) therapy. Thirty-seven patients, who switched from MDI therapy to basal insulin and dulaglutide, were retrospectively analyzed. Changes in glycosylated hemoglobin (HbA1c) and fasting plasma glucose (FPG) levels, body weight, and basal insulin dose were evaluated over 6 months. Dulaglutide was comparable to three injections of prandial insulin in terms of glycemic control (HbA1c 7.1% vs. 7.0%; 95% confidence interval [CI], –0.53 to 0.28; P=0.53). The basal insulin and dulaglutide combination resulted in a reduction in FPG levels by 9.7 mg/dL (95% CI, 2.09 to 41.54; P=0.03), in body weight by 4.9 kg (95% CI, 2.87 to 6.98; P<0.001), and in basal insulin dose by 9.52 IU (95% CI, 5.80 to 3.23; P<0.001). Once-weekly dulaglutide may be an effective alternative for thrice-daily prandial insulin in KT recipients with T2DM currently receiving MDI therapy.Hwi Seung KimJiwoo LeeChang Hee JungJoong-Yeol ParkWoo Je LeeKorean Diabetes Associationarticlediabetes mellitus, type 2dulaglutideinsulinDiseases of the endocrine glands. Clinical endocrinologyRC648-665ENDiabetes & Metabolism Journal, Vol 45, Iss 6, Pp 948-953 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	diabetes mellitus, type 2 dulaglutide insulin Diseases of the endocrine glands. Clinical endocrinology RC648-665
spellingShingle	diabetes mellitus, type 2 dulaglutide insulin Diseases of the endocrine glands. Clinical endocrinology RC648-665 Hwi Seung Kim Jiwoo Lee Chang Hee Jung Joong-Yeol Park Woo Je Lee Dulaglutide as an Effective Replacement for Prandial Insulin in Kidney Transplant Recipients with Type 2 Diabetes Mellitus: A Retrospective Review
description	Dulaglutide, a weekly injectable glucagon-like peptide-1 receptor agonist, has demonstrated effectiveness when combined with basal insulin. We examined whether the efficacy of dulaglutide is comparable to that of prandial insulin in kidney transplant (KT) recipients with type 2 diabetes mellitus (T2DM) undergoing multiple daily insulin injection (MDI) therapy. Thirty-seven patients, who switched from MDI therapy to basal insulin and dulaglutide, were retrospectively analyzed. Changes in glycosylated hemoglobin (HbA1c) and fasting plasma glucose (FPG) levels, body weight, and basal insulin dose were evaluated over 6 months. Dulaglutide was comparable to three injections of prandial insulin in terms of glycemic control (HbA1c 7.1% vs. 7.0%; 95% confidence interval [CI], –0.53 to 0.28; P=0.53). The basal insulin and dulaglutide combination resulted in a reduction in FPG levels by 9.7 mg/dL (95% CI, 2.09 to 41.54; P=0.03), in body weight by 4.9 kg (95% CI, 2.87 to 6.98; P<0.001), and in basal insulin dose by 9.52 IU (95% CI, 5.80 to 3.23; P<0.001). Once-weekly dulaglutide may be an effective alternative for thrice-daily prandial insulin in KT recipients with T2DM currently receiving MDI therapy.
format	article
author	Hwi Seung Kim Jiwoo Lee Chang Hee Jung Joong-Yeol Park Woo Je Lee
author_facet	Hwi Seung Kim Jiwoo Lee Chang Hee Jung Joong-Yeol Park Woo Je Lee
author_sort	Hwi Seung Kim
title	Dulaglutide as an Effective Replacement for Prandial Insulin in Kidney Transplant Recipients with Type 2 Diabetes Mellitus: A Retrospective Review
title_short	Dulaglutide as an Effective Replacement for Prandial Insulin in Kidney Transplant Recipients with Type 2 Diabetes Mellitus: A Retrospective Review
title_full	Dulaglutide as an Effective Replacement for Prandial Insulin in Kidney Transplant Recipients with Type 2 Diabetes Mellitus: A Retrospective Review
title_fullStr	Dulaglutide as an Effective Replacement for Prandial Insulin in Kidney Transplant Recipients with Type 2 Diabetes Mellitus: A Retrospective Review
title_full_unstemmed	Dulaglutide as an Effective Replacement for Prandial Insulin in Kidney Transplant Recipients with Type 2 Diabetes Mellitus: A Retrospective Review
title_sort	dulaglutide as an effective replacement for prandial insulin in kidney transplant recipients with type 2 diabetes mellitus: a retrospective review
publisher	Korean Diabetes Association
publishDate	2021
url	https://doaj.org/article/e0a3db234543460e922178aa4c46167d
work_keys_str_mv	AT hwiseungkim dulaglutideasaneffectivereplacementforprandialinsulininkidneytransplantrecipientswithtype2diabetesmellitusaretrospectivereview AT jiwoolee dulaglutideasaneffectivereplacementforprandialinsulininkidneytransplantrecipientswithtype2diabetesmellitusaretrospectivereview AT changheejung dulaglutideasaneffectivereplacementforprandialinsulininkidneytransplantrecipientswithtype2diabetesmellitusaretrospectivereview AT joongyeolpark dulaglutideasaneffectivereplacementforprandialinsulininkidneytransplantrecipientswithtype2diabetesmellitusaretrospectivereview AT woojelee dulaglutideasaneffectivereplacementforprandialinsulininkidneytransplantrecipientswithtype2diabetesmellitusaretrospectivereview
_version_	1718405573740855296

Dulaglutide as an Effective Replacement for Prandial Insulin in Kidney Transplant Recipients with Type 2 Diabetes Mellitus: A Retrospective Review

Ejemplares similares